New updates have been reported about Aerska.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aerska has expanded its senior leadership and governance as it pushes its brain shuttle-enabled RNA interference platform toward clinical development, appointing industry veteran Stuart Milstein as Chief Platform Officer and adding Lisa Taylor Ash to its Board of Directors. These moves follow Aerska’s recent $39 million Series A round and are aimed at sharpening platform strategy, execution, and oversight as the company advances antibody‑oligo conjugates for central nervous system diseases.
Milstein will lead platform strategy and development, drawing on two decades of oligonucleotide and RNAi experience, including leadership of RNAi Lead Development at Alnylam Pharmaceuticals and platform roles at Korro Bio and Sail Biomedicines. Ash brings board-level operational and legal expertise from scaling biotech businesses through financing, partnerships, and clinical execution, informed by senior roles at Sonoma Bio, Shape Therapeutics, Juno Therapeutics, Exelixis, and Pharmacyclics, positioning Aerska to translate its brain shuttle RNA medicines into a robust pipeline targeting historically inaccessible CNS indications.